Emerging Non-Clinical Biostatistics in Biopharmaceutical Development and Manufacturing
暫譯: 新興非臨床生物統計在生物製藥開發與製造中的應用

Yang, Harry

  • 出版商: CRC
  • 出版日期: 2020-12-18
  • 售價: $2,510
  • 貴賓價: 9.5$2,385
  • 語言: 英文
  • 頁數: 386
  • 裝訂: Quality Paper - also called trade paper
  • ISBN: 0367736640
  • ISBN-13: 9780367736644
  • 相關分類: 機率統計學 Probability-and-statistics
  • 海外代購書籍(需單獨結帳)

相關主題

商品描述

The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A comprehensive resource, it combines in-depth explanations of advanced statistical methods with real-life case studies that illustrate practical applications of these methods in QbD implementation.

商品描述(中文翻譯)

品質設計(Quality by Design, QbD)的前提是,製藥產品的品質應基於對產品及其製造過程的深入理解。本書是一本最前沿的資源,提供有關新興統計方法在QbD及風險導向製藥開發中的應用的單一資訊來源。這本全面的資源結合了對先進統計方法的深入解釋,以及實際案例研究,展示了這些方法在QbD實施中的實際應用。

作者簡介

Harry Yang, Ph.D., is senior director and head of the Non-Clinical Biostatistics Group at MedImmune, the global biologics arm of AstraZeneca headquartered in Gaithersburg, Maryland.

作者簡介(中文翻譯)

Harry Yang,博士,是MedImmune非臨床生物統計組的高級總監及負責人。MedImmune是位於馬里蘭州蓋瑟斯堡的AstraZeneca全球生物製劑部門。